Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients
Purpose This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2 -negative patients from Brazil. Methods The study comprised 126 index patients who met NCCN clin...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2021-02, Vol.185 (3), p.851-861 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 861 |
---|---|
container_issue | 3 |
container_start_page | 851 |
container_title | Breast cancer research and treatment |
container_volume | 185 |
creator | Gomes, Renan Spinola, Pricila da Silva Brant, Ayslan Castro Matta, Bruna Palma Nascimento, Caroline Macedo de Aquino Paes, Silvia Maria Bonvicino, Cibele Rodrigues dos Santos, Anna Claudia Evangelista Moreira, Miguel Angelo Martins |
description | Purpose
This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in
BRCA1/2
-negative patients from Brazil.
Methods
The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of
BRCA1/2
genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer.
Results
Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes:
ATM
(1),
CHEK2
(2),
PALB2
(1), and
TP53
(1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms.
Conclusion
A detailed mutational profile of non-
BRCA
genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort.
ATM, CHEK2, PALB2
and
TP53
are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives. |
doi_str_mv | 10.1007/s10549-020-05985-9 |
format | Article |
fullrecord | <record><control><sourceid>gale_sprin</sourceid><recordid>TN_cdi_gale_healthsolutions_A653531951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A653531951</galeid><sourcerecordid>A653531951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-5200c627acc8f64a9c146574a28bd522d158668a2327fbe3d76b7c15aaaf52063</originalsourceid><addsrcrecordid>eNqNkt-K1DAUxoso7rj6Al5IQFgE6W6SNkl7OTv4DxYU0euSpqczWdtkTNIRfSCf01O77roiIr1oOf19X07O-bLsMaOnjFJ1FhkVZZ1TTnMq6krk9Z1sxYQqcsWZuputKJMqlxWVR9mDGC8ppbWi9f3sqCgYr1hNV9n3dwEOegBngPiebCGMg3VADjpY7VIk1hHjXQQXp0hG30HQCfLk853d7vJg4yeyD9DZuPfRJusdejiIJHmyg_lH0uEraQPomIh2HfGLNTEazwyz__n7zZqd8dzBVid7AHIe9Dc7zNAeC4BtPMzu9XqI8OjqfZx9fPniw-Z1fvH21ZvN-iI3pSpSLjilRnKljal6WerasFIKVWpetZ3gvGOikrLSvOCqb6HolGyVYUJr3aNWFsfZs8V3H_znCWJqRhsNDIN24KfY8FLIEodXFIg-_QO99FNw2B1SdalYJSt5Q21xyI11vU9Bm9m0WUtRiILVgiF1-hcKnw5Gi-OH3mL9luDkN8EO9JB20Q_TvIB4G-QLaIKPMUDf7IMdcSUNo82comZJUYMpan6mqKlR9OTqalM7Qnct-RUbBKoF-AKt76Oxc36uMcyZqHhd4zLmzw1GYO5r4yeXUPr8_6VIFwsdkXCYzpsh_6P_H_P_8rw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2494718686</pqid></control><display><type>article</type><title>Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients</title><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Gomes, Renan ; Spinola, Pricila da Silva ; Brant, Ayslan Castro ; Matta, Bruna Palma ; Nascimento, Caroline Macedo ; de Aquino Paes, Silvia Maria ; Bonvicino, Cibele Rodrigues ; dos Santos, Anna Claudia Evangelista ; Moreira, Miguel Angelo Martins</creator><creatorcontrib>Gomes, Renan ; Spinola, Pricila da Silva ; Brant, Ayslan Castro ; Matta, Bruna Palma ; Nascimento, Caroline Macedo ; de Aquino Paes, Silvia Maria ; Bonvicino, Cibele Rodrigues ; dos Santos, Anna Claudia Evangelista ; Moreira, Miguel Angelo Martins</creatorcontrib><description>Purpose
This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in
BRCA1/2
-negative patients from Brazil.
Methods
The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of
BRCA1/2
genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer.
Results
Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes:
ATM
(1),
CHEK2
(2),
PALB2
(1), and
TP53
(1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms.
Conclusion
A detailed mutational profile of non-
BRCA
genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort.
ATM, CHEK2, PALB2
and
TP53
are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-020-05985-9</identifier><identifier>PMID: 33128190</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>BRCA1 protein ; Breast cancer ; Cancer ; Cancer research ; Epidemiology ; Exons ; Genes ; Genetic aspects ; Genetic diversity ; Genetic research ; Genomes ; Genomics ; Life Sciences & Biomedicine ; Medicine ; Medicine & Public Health ; mRNA ; Oncology ; Oncology, Experimental ; Ovarian cancer ; p53 Protein ; Risk groups ; Science & Technology ; Tumor proteins</subject><ispartof>Breast cancer research and treatment, 2021-02, Vol.185 (3), p.851-861</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2021 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000582992000005</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c473t-5200c627acc8f64a9c146574a28bd522d158668a2327fbe3d76b7c15aaaf52063</citedby><cites>FETCH-LOGICAL-c473t-5200c627acc8f64a9c146574a28bd522d158668a2327fbe3d76b7c15aaaf52063</cites><orcidid>0000-0003-1437-7522 ; 0000-0002-0897-469X ; 0000-0001-5062-6077 ; 0000-0003-1402-5025</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-020-05985-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-020-05985-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,39263,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33128190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gomes, Renan</creatorcontrib><creatorcontrib>Spinola, Pricila da Silva</creatorcontrib><creatorcontrib>Brant, Ayslan Castro</creatorcontrib><creatorcontrib>Matta, Bruna Palma</creatorcontrib><creatorcontrib>Nascimento, Caroline Macedo</creatorcontrib><creatorcontrib>de Aquino Paes, Silvia Maria</creatorcontrib><creatorcontrib>Bonvicino, Cibele Rodrigues</creatorcontrib><creatorcontrib>dos Santos, Anna Claudia Evangelista</creatorcontrib><creatorcontrib>Moreira, Miguel Angelo Martins</creatorcontrib><title>Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>BREAST CANCER RES TR</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in
BRCA1/2
-negative patients from Brazil.
Methods
The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of
BRCA1/2
genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer.
Results
Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes:
ATM
(1),
CHEK2
(2),
PALB2
(1), and
TP53
(1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms.
Conclusion
A detailed mutational profile of non-
BRCA
genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort.
ATM, CHEK2, PALB2
and
TP53
are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives.</description><subject>BRCA1 protein</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Epidemiology</subject><subject>Exons</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Genetic diversity</subject><subject>Genetic research</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>mRNA</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Ovarian cancer</subject><subject>p53 Protein</subject><subject>Risk groups</subject><subject>Science & Technology</subject><subject>Tumor proteins</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkt-K1DAUxoso7rj6Al5IQFgE6W6SNkl7OTv4DxYU0euSpqczWdtkTNIRfSCf01O77roiIr1oOf19X07O-bLsMaOnjFJ1FhkVZZ1TTnMq6krk9Z1sxYQqcsWZuputKJMqlxWVR9mDGC8ppbWi9f3sqCgYr1hNV9n3dwEOegBngPiebCGMg3VADjpY7VIk1hHjXQQXp0hG30HQCfLk853d7vJg4yeyD9DZuPfRJusdejiIJHmyg_lH0uEraQPomIh2HfGLNTEazwyz__n7zZqd8dzBVid7AHIe9Dc7zNAeC4BtPMzu9XqI8OjqfZx9fPniw-Z1fvH21ZvN-iI3pSpSLjilRnKljal6WerasFIKVWpetZ3gvGOikrLSvOCqb6HolGyVYUJr3aNWFsfZs8V3H_znCWJqRhsNDIN24KfY8FLIEodXFIg-_QO99FNw2B1SdalYJSt5Q21xyI11vU9Bm9m0WUtRiILVgiF1-hcKnw5Gi-OH3mL9luDkN8EO9JB20Q_TvIB4G-QLaIKPMUDf7IMdcSUNo82comZJUYMpan6mqKlR9OTqalM7Qnct-RUbBKoF-AKt76Oxc36uMcyZqHhd4zLmzw1GYO5r4yeXUPr8_6VIFwsdkXCYzpsh_6P_H_P_8rw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Gomes, Renan</creator><creator>Spinola, Pricila da Silva</creator><creator>Brant, Ayslan Castro</creator><creator>Matta, Bruna Palma</creator><creator>Nascimento, Caroline Macedo</creator><creator>de Aquino Paes, Silvia Maria</creator><creator>Bonvicino, Cibele Rodrigues</creator><creator>dos Santos, Anna Claudia Evangelista</creator><creator>Moreira, Miguel Angelo Martins</creator><general>Springer US</general><general>Springer Nature</general><general>Springer</general><general>Springer Nature B.V</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1437-7522</orcidid><orcidid>https://orcid.org/0000-0002-0897-469X</orcidid><orcidid>https://orcid.org/0000-0001-5062-6077</orcidid><orcidid>https://orcid.org/0000-0003-1402-5025</orcidid></search><sort><creationdate>20210201</creationdate><title>Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients</title><author>Gomes, Renan ; Spinola, Pricila da Silva ; Brant, Ayslan Castro ; Matta, Bruna Palma ; Nascimento, Caroline Macedo ; de Aquino Paes, Silvia Maria ; Bonvicino, Cibele Rodrigues ; dos Santos, Anna Claudia Evangelista ; Moreira, Miguel Angelo Martins</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-5200c627acc8f64a9c146574a28bd522d158668a2327fbe3d76b7c15aaaf52063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>BRCA1 protein</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Epidemiology</topic><topic>Exons</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Genetic diversity</topic><topic>Genetic research</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>mRNA</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Ovarian cancer</topic><topic>p53 Protein</topic><topic>Risk groups</topic><topic>Science & Technology</topic><topic>Tumor proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gomes, Renan</creatorcontrib><creatorcontrib>Spinola, Pricila da Silva</creatorcontrib><creatorcontrib>Brant, Ayslan Castro</creatorcontrib><creatorcontrib>Matta, Bruna Palma</creatorcontrib><creatorcontrib>Nascimento, Caroline Macedo</creatorcontrib><creatorcontrib>de Aquino Paes, Silvia Maria</creatorcontrib><creatorcontrib>Bonvicino, Cibele Rodrigues</creatorcontrib><creatorcontrib>dos Santos, Anna Claudia Evangelista</creatorcontrib><creatorcontrib>Moreira, Miguel Angelo Martins</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gomes, Renan</au><au>Spinola, Pricila da Silva</au><au>Brant, Ayslan Castro</au><au>Matta, Bruna Palma</au><au>Nascimento, Caroline Macedo</au><au>de Aquino Paes, Silvia Maria</au><au>Bonvicino, Cibele Rodrigues</au><au>dos Santos, Anna Claudia Evangelista</au><au>Moreira, Miguel Angelo Martins</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><stitle>BREAST CANCER RES TR</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>185</volume><issue>3</issue><spage>851</spage><epage>861</epage><pages>851-861</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in
BRCA1/2
-negative patients from Brazil.
Methods
The study comprised 126 index patients who met NCCN clinical criteria and tested negative for all coding exons and intronic flanking regions of
BRCA1/2
genes. Multiplex PCR-based assays were designed to cover the complete coding regions and flanking splicing sites of six genes implicated in HBOC. Sequencing was performed on HiSeq2500 Genome Analyzer.
Results
Overall, we identified 488 unique variants. We identified five patients (3.97%) that harbored pathogenic or likely pathogenic variants in four genes:
ATM
(1),
CHEK2
(2),
PALB2
(1), and
TP53
(1). One hundred and thirty variants were classified as variants of uncertain significance (VUS), 10 of which were predicted to disrupt mRNA splicing (seven non-coding variants and three coding variants), while other six missense VUS were classified as probably damaging by prediction algorithms.
Conclusion
A detailed mutational profile of non-
BRCA
genes is still being described in Brazil. In this study, we contributed to filling this gap, by providing important data on the diversity of genetic variants in a Brazilian high-risk patient cohort.
ATM, CHEK2, PALB2
and
TP53
are well established as HBOC predisposition genes, and the identification of deleterious variants in such actionable genes contributes to clinical management of probands and relatives.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>33128190</pmid><doi>10.1007/s10549-020-05985-9</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-1437-7522</orcidid><orcidid>https://orcid.org/0000-0002-0897-469X</orcidid><orcidid>https://orcid.org/0000-0001-5062-6077</orcidid><orcidid>https://orcid.org/0000-0003-1402-5025</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2021-02, Vol.185 (3), p.851-861 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_gale_healthsolutions_A653531951 |
source | SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
subjects | BRCA1 protein Breast cancer Cancer Cancer research Epidemiology Exons Genes Genetic aspects Genetic diversity Genetic research Genomes Genomics Life Sciences & Biomedicine Medicine Medicine & Public Health mRNA Oncology Oncology, Experimental Ovarian cancer p53 Protein Risk groups Science & Technology Tumor proteins |
title | Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T02%3A09%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20germline%20variants%20in%20consensus%20moderate-to-high-risk%20predisposition%20genes%20to%20hereditary%20breast%20and%20ovarian%20cancer%20in%20BRCA1/2-negative%20Brazilian%20patients&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Gomes,%20Renan&rft.date=2021-02-01&rft.volume=185&rft.issue=3&rft.spage=851&rft.epage=861&rft.pages=851-861&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-020-05985-9&rft_dat=%3Cgale_sprin%3EA653531951%3C/gale_sprin%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2494718686&rft_id=info:pmid/33128190&rft_galeid=A653531951&rfr_iscdi=true |